Neonatal Infectious Diseases/Immunology
Neonatal Infectious Diseases/Immunology 4
Haejung Yoon (she/her/hers)
University of North Carolina at Chapel Hill School of Medicine
Cary, North Carolina, United States
Conclusion(s): The proportion of cCMV infants treated with ganciclovir and valganciclovir has increased over time. Our data support previous studies identifying neutropenia as an adverse effect of ganciclovir. We did not find a difference in the odds of thrombocytopenia or hepatic dysfunction before and during treatment.